This narrative review represents an output from the International Association for the Study of
Pain's global task force on the use of cannabis, cannabinoids, and cannabis-based …

A great need exists for the development of new medications to treat pain resulting from
various disease states and types of injury. Given that the endogenous cannabinoid (that is …

Cannabinoid co-administration may enable reduced opioid doses for analgesia. This
updated systematic review on the opioid-sparing effects of cannabinoids considered …

The type 2 cannabinoid receptor (CB2R) was initially regarded as a peripheral cannabinoid
receptor. However, recent technological advances in gene detection, alongside the …

Despite low levels of cannabinoid receptor type 2 (CB2R) expression in the central nervous
system in human and rodents, a growing body of evidence shows CB2R involvement in …

Chronic pain is a complex sensory, cognitive, and emotional experience that imposes a
great personal, psychological, and socioeconomic burden on patients. An estimated 1.5 …

Introduction: The complexity of the endocannabinoid (eCB) system is becoming better
understood and new drivers of eCB signaling are emerging. Modulation of the activities of …

Substance use disorder (SUD) is a major public health crisis worldwide, and effective
treatment options are limited. During the past 2 decades, researchers have investigated the …

Chronic pain affects a significant percentage of the United States population, and available
pain medications like opioids have drawbacks that make long-term use untenable …

Chronic neuropathic pain (NP) is an increasingly prevalent disease and leading cause of
disability which is challenging to treat. Several distinct classes of drugs are currently used for …